Search - tctmd.com

Displaying 121 - 132 of 132

Sort: Relevancy | Date

News Conference News TCT 2012

Israeli Innovations Include ‘Cath Lab of the Future,’ Stent and Digital Developments

October 22, 2012

News Conference News TCT 2012

COURAGE, FAME: Revascularization More Effective Than OMT

October 22, 2012

Presentation TCT 2012

Four-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease and/or Left Main Disease

Presenter: David R. Holmes, Brad Vazales, Louis A. Cannon, Elisabeth Stahle, Marie-Claude Morice, Michael J. Mack, Ted E. Feldman, A. Pieter Kappetein, Antonio Colombo, Keith D. Dawkins, Friedrich W. Mohr, Patrick W. Serruys

January 03, 2012

News Conference News

ACCEL-BLEED: Mild Bleeding Correlated with Platelet Reactivity One Month Post PCI

November 22, 2011

News Conference News

Two New SES Show Improvement Over First-Generation Stents

Yael L. Maxwell

November 10, 2011

News Conference News

Complications After TAVR: Manageable, But Important to Consider

November 09, 2011

News Conference News

Safety, Efficacy Reported with FIREHAWK SES

November 08, 2011

News Conference News

Caution Urged in Widespread Adoption of TAVR

November 08, 2011

News Conference News

C-Pulse Heart Assist Device Improved Ventricular Remodeling, HF Symptoms

November 07, 2011

News Conference News

No Change Seen in European TAVR Clinical Use Patterns

November 06, 2011

News Conference News

New Stem Cell Therapies Promising in Severe Heart Disease

November 06, 2011

News Conference News

Coming to Grips with CLOSURE I: PFO Device Plus Medical Therapy Not Superior to Medical Therapy Alone

November 06, 2011

Advertisement

Israeli Innovations Include ‘Cath Lab of the Future,’ Stent and Digital Developments

COURAGE, FAME: Revascularization More Effective Than OMT

Four-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease and/or Left Main Disease

ACCEL-BLEED: Mild Bleeding Correlated with Platelet Reactivity One Month Post PCI

Two New SES Show Improvement Over First-Generation Stents

Complications After TAVR: Manageable, But Important to Consider

Safety, Efficacy Reported with FIREHAWK SES

Caution Urged in Widespread Adoption of TAVR

C-Pulse Heart Assist Device Improved Ventricular Remodeling, HF Symptoms

No Change Seen in European TAVR Clinical Use Patterns

New Stem Cell Therapies Promising in Severe Heart Disease

Coming to Grips with CLOSURE I: PFO Device Plus Medical Therapy Not Superior to Medical Therapy Alone

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content